Clinical study of salvage second allogeneic hematopoietic stem cell transplantation in 17 cases
10.12464/j.issn.1674-7445.2025230
- VernacularTitle:挽救性二次异基因造血干细胞移植17例的临床研究
- Author:
Wenqiong WANG
1
;
Wei LIU
1
;
Huihui LIU
1
;
Xiaoying YANG
1
;
Shuanglian XIE
1
;
Hongtao LING
1
;
Yiming ZHAO
1
;
Yujun DONG
1
Author Information
1. Department of Hematology, Peking University First Hospital, Beijing 100034, China.
- Publication Type:OriginalArticle
- Keywords:
Allogeneic hematopoietic stem cell transplantation;
Second transplantation;
Acute leukemia;
Relapse fatality;
Transplant-related fatality;
Graft-versus-host disease;
Transplant-associated thrombotic microangiopathy;
Donor lymphocyte infusion
- From:
Organ Transplantation
2026;17(1):124-132
- CountryChina
- Language:Chinese
-
Abstract:
Objective To summarize and analyze the efficacy and influencing factors of second allogeneic hematopoietic stem cell transplantation (allo-HSCT) for acute leukemia relapsing after the first allo-HSCT. Methods Clinical data of 17 patients with acute leukemia who underwent second allo-HSCT at Peking University First Hospital from January 2005 to December 2024 were retrospectively analyzed. Results Among the 17 patients, 7 achieved long-term disease-free survival after second transplantation. The median progression-free survival after successful second transplantation was 7 months (range 8 days to 69 months). The relapse fatality was 24%, and the transplant-related fatality was 35%. Conclusions Second transplantation is an effective treatment for relapsed and refractory acute leukemia, but the relapse fatality and transplant-related fatality remain high. Patient age, time of relapse after the first transplantation and disease status before second transplantation are all factors that affect the efficacy of second transplantation. Younger age, late relapse and complete remission of disease before second transplantation are all beneficial for long-term disease-free survival after second transplantation.
